Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.